(Q38036942)

27 August 2017

title

Molecular-targeted therapies for ovarian cancer: prospects for the future (English)

1 reference

27 August 2017

1 reference

Tamotsu Sudo

1

1 reference

27 August 2017

publication date

23 August 2012

1 reference

International Journal of Clinical Oncology

27 August 2017

published in

1 reference

27 August 2017

volume

17

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

424-429

1 reference

27 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Systemic treatment policies in ovarian cancer: the next 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

21 January 2018

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Ovarian cancer: strategies for overcoming resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Activation of Cdh1-dependent APC is required for G1 cell cycle arrest and DNA damage-induced G2 checkpoint in vertebrate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Activation of AKT kinases in cancer: implications for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

DNA repair deficiency as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Taking down tumors: vascular disrupting agents entering clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Vascular-targeting therapies for treatment of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Vascular disrupting agents: a new class of drug in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0461-1

Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

21 January 2018

1 reference

12 December 2020

An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

12 December 2020

Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis

1 reference

12 December 2020

A novel technique for the enrichment of primary ovarian cancer cells.

1 reference

12 December 2020

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer

1 reference

12 December 2020

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model

1 reference

12 December 2020

Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.

1 reference

12 December 2020

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

1 reference

12 December 2020

BRCA1 promoter methylation predicts adverse ovarian cancer prognosis

1 reference

12 December 2020

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

12 December 2020

Are all pelvic (nonuterine) serous carcinomas of tubal origin?

1 reference

12 December 2020

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

12 December 2020

10.1007/S10147-012-0461-1

Identifiers

DOI

1 reference

27 August 2017

1 reference